Cumberland Pharmaceuticals Inc. has closed a strategic transaction with an affiliate of Apotex Inc., selling its U.S. branded pharmaceutical products for $100 million in cash. The transaction, approved by Cumberland's shareholders with over 99% of votes cast in favor, allows the company to strengthen its financial position. Cumberland will now focus its resources on developing its pipeline programs, particularly ifetroban, for rare and progressive diseases. The company has retained assets related to its ifetroban product candidates and its majority ownership in Cumberland Emerging Technologies Inc. The sale involved FDA-approved products including Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, and Vibativ. As part of the transaction, two Vice Presidents, Chris T. Bitterman and James L. Herman, will resign from Cumberland on July 31, 2026, and be hired by an Apotex affiliate. Cumberland also terminated and repaid its outstanding obligations of approximately $5.3 million under its Revolving Credit Loan Agreement with Pinnacle Bank.